CVE-2023-38958
CVE-2023-38958 is a medium-severity vulnerability in Zkteco Bioaccess Ivs with a CVSS 3.x base score of 5.3. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-863.
Key facts
- Severity: Medium (CVSS 3.x base score 5.3)
- EPSS exploit prediction: 0% (23rd percentile)
- Actively exploited: Not listed in CISA KEV
- Weakness: CWE-863
- Affected product: Zkteco Bioaccess Ivs
- Published:
- Last modified:
Description
An access control issue in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to arbitrarily close and open the doors managed by the platform remotely via sending a crafted web request.
Frequently asked questions
- What is CVE-2023-38958?
- An access control issue in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to arbitrarily close and open the doors managed by the platform remotely via sending a crafted web request.
- How severe is CVE-2023-38958?
- CVE-2023-38958 has a CVSS 3.x base score of 5.3, rated medium severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is none, integrity low, and availability none.
- Is CVE-2023-38958 being actively exploited?
- It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (23rd percentile), an estimate of the probability of exploitation in the next 30 days.
- What products are affected by CVE-2023-38958?
- CVE-2023-38958 affects Zkteco Bioaccess Ivs. See the affected-products list for the exact vulnerable versions.
- How do I fix CVE-2023-38958?
- Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
- When was CVE-2023-38958 published?
- CVE-2023-38958 was published on 2023-08-03 and last updated on 2026-07-09.
References
Affected products (1)
- cpe:2.3:a:zkteco:bioaccess_ivs:3.3.1:*:*:*:*:*:*:*
More vulnerabilities in Zkteco Bioaccess Ivs
- CVE-2023-38954 — Critical (CVSS 9.8): ZKTeco BioAccess IVS v3.3.1 was discovered to contain a SQL injection vulnerability.
- CVE-2023-38956 — High (CVSS 7.5): A path traversal vulnerability in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to read arbitrary files…
- CVE-2023-38955 — High (CVSS 7.5): ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to obtain sensitive information about all managed devices,…
All CVEs affecting Zkteco Bioaccess Ivs →
Other CWE-863 (Incorrect Authorization) vulnerabilities
- CVE-2026-48286 — Critical (CVSS 10.0): Adobe Campaign Classic (ACC) versions 7.4.3 build 9396 and earlier are affected by an Incorrect Authorization…
- CVE-2026-48303 — Critical (CVSS 10.0): Adobe Campaign Classic (ACC) versions 7.4.3 build 9394 and earlier are affected by an Incorrect Authorization…
- CVE-2026-44330 — Critical (CVSS 10.0): free5GC is an open-source implementation of the 5G core network. Prior to 4.2.2, free5GC's NEF mounts the…
- CVE-2026-46595 — Critical (CVSS 10.0): Previously, CVE-2024-45337 fixed an authorization bypass for misused ssh server configurations; if any other type of…
- CVE-2026-33105 — Critical (CVSS 10.0): Improper authorization in Microsoft Azure Kubernetes Service allows an unauthorized attacker to elevate privileges over…
- CVE-2026-32213 — Critical (CVSS 10.0): Improper authorization in Azure AI Foundry allows an unauthorized attacker to elevate privileges over a network.
Browse all CWE-863 (Incorrect Authorization) vulnerabilities →